130 likes | 231 Vues
Explore the impact and regulations of biotechnology in the EU, focusing on ethical issues, tissue engineering, and economic significance. Discover how principles and directives shape the educational landscape at prestigious universities.
E N D
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat theUniversity of Pécs and at the University of Debrecen Identificationnumber: TÁMOP-4.1.2-08/1/A-2009-0011
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat theUniversity of Pécs and at the University of Debrecen Identification number: TÁMOP-4.1.2-08/1/A-2009-0011 Dr. Judit Pongrácz Threedimensionaltissuecultures and tissueengineering – Lecture 27 Ethicalissues
No ethicalissuesraised • Autologouscells • No life threateningconditions
More ethicalquestions • Advanced human tissueengineeringtherapiesmayalso be usedforlife-threateningconditions • Embryonicstemcells • Xenogeneiccells
Regulationin Europe • Best regulated at European level • European framework laws • Directives adopted by the European Commission and the European Parliament must be incorporated in national law
The most relevantdocuments • Charter of FundamentalRightsofthe EU • ConventiononBiomedicine
Rulingin 2011 • A singlecellfrom an embryocan be consideredas a human being.
USA • Embryonicstemcellscannot be used • Onlyestablishedcelllinescan be usedinresearch • Adultstemcellscan be appliedinresearch
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat theUniversity of Pécs and at the University of Debrecen Identification number: TÁMOP-4.1.2-08/1/A-2009-0011 Dr. Judit Pongrácz Threedimensionaltissuecultures and tissueengineering – Lecture 28 Economicsignificance
Biotechnology Medical Pharmaceutical Agricultural, etc
Significanceinthe US In2001, 3,300 scientists and supportstaffworkedintissueengineeringalone Over 70 start-upcompanies Investment of 3.5 billionUS dollars
Significanceinthe EU Fastgrowing STILL No venturecapitalin Europe
Big Pharma Refocusingtocellbasedtherapies Noveltherapeuticapproachesjustintreatment of diabeticpatientsalone